ClinicalTrials.gg
Status unknownNCT04341428Updated Sep 3, 2020

Study to Evaluate the Efficacy and Safety of DWP14012 on Maintaining Healing in Subjects With Healed Erosive Esophagitis

A Phase 3 interventional study of DWP14012 20 mg and DWP14012 20 mg placebo in Healed Erosive Esophagitis, sponsored by Daewoong Pharmaceutical Co. LTD.. Status unknown at 1 site in Korea, Republic of. Open to participants aged 19 Years to 75 Years. Per ClinicalTrials.gov, last updated 2020-09-03.

Sponsored by Daewoong Pharmaceutical Co. LTD. · Phase 3, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Jul 2020), so the status shown — last known as Recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
406
Allocation
Randomized
Ages
19 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 12 studies in Esophagitis with a site in Korea, Republic of — none open to participants now, none under way, none of them phase 3. Esophagitis · Korea, Republic of.

Planned enrollment
3rd of 12
406 · median 290
Started
2020
with 1 other
Phase 3
9 of 12
none open now
Registered
9th of 12
by date
Lead sponsor
3 of 12
Daewoong Pharmaceutical Co. LTD.

Among the 12 studies in Esophagitis with a site in Korea, Republic of, this one is the 3rd largest by planned enrollment, is one of 2 that started in 2020, is one of 9 in phase 3, and was the 9th registered.

Esophagitis

123 studies on the registry are indexed under Esophagitis; 15 are open to participants now.

Browse Esophagitis studies →

Open to participants now

None of the 12 studies in Esophagitis with a site in Korea, Republic of is open now. The open studies under Esophagitis, anywhere →

Who these studies take

Of the 10 Esophagitis studies recruiting now, 6 (60%) set no upper age limit and 4 (40%) stop at 75 or younger; 2 take children under 18; 1 takes healthy volunteers.

This study: 19 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 12 studies in Esophagitis with a site in Korea, Republic of as a file.
02

Study summary

This study aims to demonstrate the noninferiority of DWP14012 to Lansoprazole 15 mg in the maintenance effect of treatment and confirm the safety of DWP14012 in patients with healed erosive esophagitis confirmed on EGD after medication treatment.

03

Conditions studied

  • Healed Erosive Esophagitis

Browse trials for

04

Who can participate

Ages eligible
19 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male and female adults aged 19 to 75 years, at the date the written form is signed
  2. Subjects with erosive esophagitis (LA Grade A-D) confirmed on EGD within 12 weeks from Visit 2 (randomization day)
  3. Subjects with healed erosive esophagitis (no mucosal break observed according to LA classification) confirmed on EGD performed within 10 days before Visit 2 (randomization day) after receiving the standard dose of medicinal products of erosive esophagitis (PPI, P-CAB, etc.) for 4 to 8 weeks for the treatment of erosive esophagitis

Exclusion criteria

Exclusion Criteria:

  1. Subjects who have Barrett's esophagus (> 3 cm), gastroesophageal varix, esophagostenosis, ulcer stenosis, active peptic ulcer, acute gastrointestinal bleeding, or a malignant tumor upon EGD screening
  2. Subjects who have inflammatory bowel disease (Crohn disease, ulcerative colitis, etc.), irritable bowel syndrome (IBS), primary esophageal motility, or pancreatitis.
  3. Subjects with history of disease of hepatic, renal, nervous, pulmonary, endocrine, hemato-oncologic, cardiovascular or urinary system
  4. Subjects who have had a malignant tumor in the last 5 years
  5. Subjects who must continue to take non-steroidal anti-inflammatory drugs (aspirin, etc.), antithrombotic drugs, etc. during the study period (A low dose of aspirin [100 mg/day] which has been administered for prophylactic purpose before study entry is allowed)
  6. Subjects who cannot stop the existing erosive esophagitis treatment being taken
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
406 participants (estimated)

Study arms

  • Experimental
    DWP14012 20mg

    Orally, once daily

    Drug: DWP14012 20 mg · Drug: Lansoprazole 15 mg Placebo

  • Active comparator
    Lansoprazole 15mg

    Orally, once daily

    Drug: DWP14012 20 mg placebo · Drug: Lansoprazole 15 mg

Interventions

  • DWP14012 20 mg, tablet, orally, once daily for up to 24 weeks

  • DrugDWP14012 20 mg placebo

    DWP14012 20 mg placebo-matching tablet, orally, once daily for up to 24 weeks

  • Lansoprazole 15 mg capsule, orally, once daily for up to 24 weeks

  • DrugLansoprazole 15 mg Placebo

    Lansoprazole 15 mg Placebo capsule, orally, once daily for up to 24 weeks

06

What researchers measure

Primary outcomes

  1. Proportion (%) of subjects with remission maintained on esophagogastroduodenoscopy by Week 24

    Time frame: at 24 week

Secondary outcomes

  1. Proportion (%) of subjects with remission maintained on esophagogastroduodenoscopy by Week 12

    Time frame: at 12 week

Other outcomes

  1. GERD-Health related quality life(HRQL)

    Changes from baseline in the total score of GERD-HRQL at Weeks 4, 12, and 24(The total score could range from 0 to 50 and lower score was evaluated as higher quality of life)

    Time frame: at Weeks 4, 12, and 24

  2. Assessment on symptoms

    Proportions of subjects without the major symptoms (heartburn and/or acid regurgitation) at Weeks 4, 12, and 24

    Time frame: Weeks 4, 12, and 24

07

Study locations

1 of 1 sites recruiting
  • The Catholic University of Korea, Yeouido ST. Mary's Hospital
    Seoul, 07345, Korea, Republic of
    Recruiting
    • JINIL KIM, M.D., Ph.D. · Contact
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2020 (actual). Primary completion is estimated for Aug 2021, 13 months after the start.

Of 18 phase 3 interventional studies under Esophagitis, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 34. This study's planned 13 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 9, 2020
First posted
Apr 10, 2020
StartActual
Jul 2, 2020
Primary completionEst.
Aug 30, 2021
CompletionEst.
Dec 30, 2021
Last update
Sep 3, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 3, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04341428
Responsible party
Sponsor
First posted
Apr 10, 2020
Start date
Jul 2, 2020
Primary completion
Aug 30, 2021 (estimated)
Completion
Dec 30, 2021 (estimated)
Last update
Sep 3, 2020

Study contacts

Oh-Young Lee
Contact
leeoy@hanyang.ac.kr
82-2-2290-8637

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Jul 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Fexuprazan

Start the discussion